The overall mutation burden of metastatic lesions was significantly higher than primary tumors in luminal B and in TNBC breast cancer patients, whereas there was no difference among luminal A and HER2+ patients (Fig. 1b). This evidence concerns the gene ERBB2 and breast cancer.